Answers are grounded in this paper and cite their sources.
The financial burden associated with orally administered anticancer drugs can be overwhelming for Medicare beneficiaries. Policies adding an out-of-pocket spending cap to Part D have been proposed, and Congress could permit price negotiation for anticancer drugs.
No takes yet. Share an insight, caveat, or question.
Stacie B. Dusetzina (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: